
MOBI Stock Forecast & Price Target
MOBI Analyst Ratings
Bulls say
Mobia Medical is attractive because it occupies a first-mover, effectively category-defining position in chronic stroke recovery, with Vivistim as the only FDA-approved VNS platform and a large unmet need among roughly 9M ischemic stroke survivors. Clinical feedback and two-year VNS-REHAB data support durable functional gains, while reimbursement friction has eased and the company has already surpassed 1,000 implants since its full commercial launch in 2023, indicating improving adoption. The financial setup also looks compelling, as revenue reached $13.5M in 2Q26 and management has guided FY26 sales to $54M-$56M, while expectations call for about 46% top-line CAGR through FY28 on expanding territories and better payer dynamics.
Bears say
Mobia Medical is vulnerable to downside if Vivistim adoption at new stroke centers is slower than modeled, since all revenue comes from this single product and weaker-than-expected penetration would directly pressure growth. Its outlook also worsens if the broader stroke-recovery market expands more slowly, or if faster average selling price degradation compresses margins and offsets unit growth. In addition, longer product development timelines and higher operating expense spend than modeled could delay operating leverage, increase cash burn, and make the company’s already concentrated business model more fragile.
This aggregate rating is based on analysts' research of Mobia Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
MOBI Analyst Forecast & Price Prediction
Start investing in MOBI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Mobia Medical Inc (MOBI) Forecast
MOBI Analyst Forecast & Price Prediction
Start investing in MOBI
Order type
Buy in
Order amount
Est. shares
0 shares